Bioatla Inc (BCAB) - Total Assets
Based on the latest financial reports, Bioatla Inc (BCAB) holds total assets worth $8.57 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Bioatla Inc balance sheet independence to measure how much of total assets are equity-financed.
Bioatla Inc - Total Assets Trend (2018–2025)
This chart illustrates how Bioatla Inc's total assets have evolved over time, based on quarterly financial data. Check Bioatla Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Bioatla Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Bioatla Inc's total assets of $8.57 Million consist of 58.0% current assets and 42.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Bioatla Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BCAB stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioatla Inc's current assets represent 58.0% of total assets in 2025, a decrease from 76.1% in 2018.
- Cash Position: Cash and equivalents constituted 51.5% of total assets in 2025, down from 65.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bioatla Inc Competitors by Total Assets
Key competitors of Bioatla Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Bioatla Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.15 | 2.35 | 5.87 |
| Quick Ratio | 0.15 | 2.35 | 5.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-17.60 Million | $21.53 Million | $176.18 Million |
Bioatla Inc - Advanced Valuation Insights
This section examines the relationship between Bioatla Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -73.6% |
| Total Assets | $13.83 Million |
| Market Capitalization | $5.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioatla Inc's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bioatla Inc's assets decreased by 73.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioatla Inc (2018–2025)
The table below shows the annual total assets of Bioatla Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $13.83 Million | -73.62% |
| 2024-12-31 | $52.42 Million | -56.19% |
| 2023-12-31 | $119.66 Million | -46.99% |
| 2022-12-31 | $225.74 Million | -11.27% |
| 2021-12-31 | $254.42 Million | +3.87% |
| 2020-12-31 | $244.94 Million | +2523.58% |
| 2019-12-31 | $9.34 Million | -43.88% |
| 2018-12-31 | $16.64 Million | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more